BioSpace News Archive

Secarna Pharmaceuticals announced today that results from preclinical studies targeting ROR(gamma)t with an innovative antisense oligonucleotide approach will be presented at the 5th European Congress of Immunology (ECI).

Researchers from Kanazawa University report in Journal of Neuroscience performed a microdialysis study on mice to determine mechanisms underlying the inflammatory response in the brain associated with fever that might be used to develop new strategies for treatment.

ICLUSIG to be made available to all refractory/relapsed Ph+ ALL patients from September 1, 2018

Thermo Fisher Scientific Inc. has signed a definitive agreement with BD (Becton, Dickinson and Company)

GENFIT today announces its participation in numerous investor healthcare conferences both in Europe and the United States.

Taiwan Liposome Company, Ltd. today announced that it will feature a poster presentation covering the complete dataset from its Phase I/II study of the company’s lead product candidate, TLC599, in patients with knee osteoarthritis at the 20th Asia Pacific League of Associations for Rheumatology Congress (APLAR),

Omeros Corporation (NASDAQ: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 16th Annual Morgan Stanley Global Healthcare Conference in New York next week.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, will report financial results for the three and twelve months ended June 30, 2018, which is the Company’s fourth quarter of fiscal year 2018

BDD Pharma, a privately-owned drug delivery company specializing in the development of modified and controlled release oral formulations, and Cingulate Therapeutics, a clinical stage biopharmaceutical company, today announced that the companies have completed a license agreement for BDD’s OralogiK(TM) timed drug delivery technology

Hub International Limited (Hub), a leading global insurance brokerage, announced today that it has acquired Access Insurance Brokers Inc. (Access Insurance). Terms of the transaction were not disclosed.